Sino Biological, Inc.Sino Biological US, Inc. proudly unveils ProPure™, an industry-leading line of ultra-pure, endotoxin-free recombinant proteins, fully produced in the USA at its state-of-the-art Center for Bioprocessing (C4B) facility in Houston, Texas.
ions.bioIions.bio was founded in 2024 and is located in the Innovation and Startup Centre IZB in Planegg-Martinsried.
![product_02_bg[63]](https://european-biotechnology.com/wp-content/uploads/2025/05/product_02_bg63-180x180.png "product_02_bg[63]")
Spatial precision in cell analysis is revolutionizing biomedical research. SLACS (Spatially-resolved Laser Activated Cell Sorting) uniquely isolates live microniches within tissues, preserving spatial context and enabling deep biological insights.
Customized Enzymes and Reagents from New England Biolabs. Creating the right partnership is essential when pioneering a new life science product.
Day 1 at Chemspec Europe 2025 opened with a dynamic programme that underscored the growing importance of collaboration, innovation, and strategic foresight in the fine and speciality chemicals sector. From thought-provoking keynote sessions to in-depth technical discussions, the conference provided a platform for knowledge exchange and future-oriented dialogue among key players in the industry.
Vetter Pharma International GmbHThe award jury recognizes strategic and sustainable corporate management.
Sino BiologicalAntibody-Drug Conjugates (ADCs) have been transformative in oncology, offering targeted cancer treatments that enhance efficacy while sparing healthy cells. However, the potential of ADCs extends well beyond cancer care. From autoimmune diseases to metabolic disorders, advancements in ADC technology are paving the way for breakthroughs across a range of therapeutic areas. This article explores how ADCs are redefining treatment paradigms and improving patient outcomes in diverse fields of medicine.
GettyImagesExplore the evolving world of GLP-1 receptor agonists in Issue 42 of The Altascientist, featuring insights on their expanding applications, early-phase development, and real-world case studies.
3PBIOVIAN, a leading Contract Development and Manufacturing Organization (CDMO) with locations in Pamplona (Spain) and Turku (Finland), has been awarded the prestigious CDMO Leadership Award 2025 in the “Cell & Gene Therapy International” category. This award recognizes the excellence of the services that 3PBIOVIAN provides to the Advanced Therapies industry, solidifying its position as a leader in the international sector.
Eleva GmbHFreiburg-based Eleva relies on its moss-based platform for the development of new biologics both independently and with partners. A new alliance with Spanish CDMO 3PBIOVIAN now secures clinical production capacity for both activities.